Financial Daily from THE HINDU group of publications
Sunday, Oct 09, 2005


News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements


FDA nod for Ranbaxy drug

Our Bureau

NEW DELHI: Ranbanxy Laboratories Ltd has received an approval from the US Food and Drug Administration to manufacture and market glimepiride tablets used for diabetes.

The Ranbaxy formulations have the same therapeutic effect as that of Aventis Pharmaceuticals's Amaryl tablets, which has total annual market sales of $349.5 million. Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with non-insulin-dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone.

In a statement, Mr Venkat Krishnan, Vice-President, Ranbaxy Inc of the US, said, "We are pleased to receive this final approval for glimepiride tablets.

"This product represents an interesting opportunity for Ranbaxy, in which we will offer a number of strengths of this oral hypoglycemic agent to support dosing flexibility that will benefit both prescribers and patients."

Glimepiride will be launched immediately, and the company will now make a concerted effort to reach key buyers as quickly as possible, said Ranbaxy.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Tata Safari Dicor

Stories in this Section
FDA nod for Ranbaxy drug


MMTC plans to acquire coal mines abroad
33 pc independent directors on co boards — Govt studying Irani panel proposal
Mittal Steel signs MoU with Jharkhand for Rs 40,000-cr plant
Indo-Russian vehicles venture to begin trial production
ONGC plans two coal gasification projects in TN, AP
GIPCL to tap market with equity issue


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line